Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP215355.RAV_vL9b3O98rAttKvz4FMlizFUgGW4flkLuy-DZMDsqs130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP215355.RAV_vL9b3O98rAttKvz4FMlizFUgGW4flkLuy-DZMDsqs130_assertion type Assertion NP215355.RAV_vL9b3O98rAttKvz4FMlizFUgGW4flkLuy-DZMDsqs130_head.
- NP215355.RAV_vL9b3O98rAttKvz4FMlizFUgGW4flkLuy-DZMDsqs130_assertion description "[This review focuses on ALK rearrangements in NSCLC, starting with the discovery of the EML4-ALK fusion oncogene, and culminating in the recent validation of ALK as a therapeutic target in patients with ALK-rearranged NSCLC.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP215355.RAV_vL9b3O98rAttKvz4FMlizFUgGW4flkLuy-DZMDsqs130_provenance.
- NP215355.RAV_vL9b3O98rAttKvz4FMlizFUgGW4flkLuy-DZMDsqs130_assertion evidence source_evidence_literature NP215355.RAV_vL9b3O98rAttKvz4FMlizFUgGW4flkLuy-DZMDsqs130_provenance.
- NP215355.RAV_vL9b3O98rAttKvz4FMlizFUgGW4flkLuy-DZMDsqs130_assertion SIO_000772 21288922 NP215355.RAV_vL9b3O98rAttKvz4FMlizFUgGW4flkLuy-DZMDsqs130_provenance.
- NP215355.RAV_vL9b3O98rAttKvz4FMlizFUgGW4flkLuy-DZMDsqs130_assertion wasDerivedFrom befree-20140225 NP215355.RAV_vL9b3O98rAttKvz4FMlizFUgGW4flkLuy-DZMDsqs130_provenance.
- NP215355.RAV_vL9b3O98rAttKvz4FMlizFUgGW4flkLuy-DZMDsqs130_assertion wasGeneratedBy ECO_0000203 NP215355.RAV_vL9b3O98rAttKvz4FMlizFUgGW4flkLuy-DZMDsqs130_provenance.